-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In recent years, with the accelerated adjustment of the National Medical Insurance Catalogue, some adjuvant drugs and key monitoring drugs are being withdrawn from the Medical Insurance Catalog at an accelerated pace, making room for drugs that have real therapeutic effects in clinical practice
.
According to this trend, the industry believes that in 2022, provinces will also gradually adjust their local medical insurance catalogues, and a large number of supplementary drugs in the medical insurance catalogue will be gradually transferred out
.
It is understood that from January 2021, a large number of pharmaceutical companies have begun to officially implement the new version of the medical insurance catalog
.
For example, in the "Notice on Doing a Good Job in Implementation" issued by the Heilongjiang Provincial Medical Security Bureau and the Provincial Human Resources and Social Security Department, a total of 74 kinds of drugs have been newly transferred in and 11 kinds of drugs have been transferred out
.
Of course, in addition to the continuous adjustment of the medical insurance catalogue, which will accelerate the reform of the pharmaceutical market, the industry believes that with the continuous advancement of medical reform policies such as volume purchases, it will also accelerate the merger and integration of Chinese pharmaceutical companies
.
For example, according to the "Guiding Opinions on Promoting the High-Quality Development of the Drug Circulation Industry During the "14th Five-Year Plan" Period" announced by the Ministry of Commerce, by 2025, 1 to 3 companies will exceed 500 billion yuan, and 5 to 10 companies will exceed 100 billion yuan.
Yuan's large-scale digital and comprehensive drug distribution enterprises, 5-10 specialized and diversified drug retail chain enterprises with over 50 billion yuan, and about 100 intelligent, characteristic and platform-based drug supply chain service enterprises , the improvement of industry concentration has become the development direction currently guided by the country, which will accelerate the elimination of the pharmaceutical industry
.
It is understood that, in fact, a pharmaceutical company recently issued an announcement saying that due to the company's lower-than-expected performance, a goodwill impairment of 130 million yuan was provided
.
In general, under the pressure of a series of policies, the elimination process of the pharmaceutical market will continue to accelerate
.
Especially in the next 3 to 5 years, the knockout stage of the pharmaceutical industry will continue to accelerate, or 90% of generic drugs will withdraw from the market
.
It is worth noting that, at the same time, with the policy of consistency evaluation becoming clearer and the rules of drug bidding becoming more and more perfect, returning to value will be the future development direction of the industry
.
In this context, in order to obtain more development opportunities, enterprises must either expand the scale, improve quality, control costs, and improve supply management; or increase investment in research and development of new drugs; or enter the market and expand the field of drug research and development and sales
.
Among the many ways out, analysts believe that because national policies have been focusing on medicine in recent years, innovation will play a decisive role in the development of China's pharmaceutical industry, which will further promote the development of China's innovative drug market
.
In order to seize new market development opportunities, companies need to continuously increase investment in innovative drug research and development or promote the development of generic drugs with core values
.
It is reported that in fact, a large number of pharmaceutical companies have already transformed into innovative drugs and have gradually entered the harvest period
.
Taking Hengrui Medicine as an example, its innovative drug pipeline layout is already very rich.
In addition to blockbuster products such as PD-1, apatinib, pyrotinib, and fluzoparib, its innovative drug pipeline also covers A variety of indications have been developed, and the clinical progress of many potential products is also very smooth
.
.
According to this trend, the industry believes that in 2022, provinces will also gradually adjust their local medical insurance catalogues, and a large number of supplementary drugs in the medical insurance catalogue will be gradually transferred out
.
It is understood that from January 2021, a large number of pharmaceutical companies have begun to officially implement the new version of the medical insurance catalog
.
For example, in the "Notice on Doing a Good Job in Implementation" issued by the Heilongjiang Provincial Medical Security Bureau and the Provincial Human Resources and Social Security Department, a total of 74 kinds of drugs have been newly transferred in and 11 kinds of drugs have been transferred out
.
Of course, in addition to the continuous adjustment of the medical insurance catalogue, which will accelerate the reform of the pharmaceutical market, the industry believes that with the continuous advancement of medical reform policies such as volume purchases, it will also accelerate the merger and integration of Chinese pharmaceutical companies
.
For example, according to the "Guiding Opinions on Promoting the High-Quality Development of the Drug Circulation Industry During the "14th Five-Year Plan" Period" announced by the Ministry of Commerce, by 2025, 1 to 3 companies will exceed 500 billion yuan, and 5 to 10 companies will exceed 100 billion yuan.
Yuan's large-scale digital and comprehensive drug distribution enterprises, 5-10 specialized and diversified drug retail chain enterprises with over 50 billion yuan, and about 100 intelligent, characteristic and platform-based drug supply chain service enterprises , the improvement of industry concentration has become the development direction currently guided by the country, which will accelerate the elimination of the pharmaceutical industry
.
It is understood that, in fact, a pharmaceutical company recently issued an announcement saying that due to the company's lower-than-expected performance, a goodwill impairment of 130 million yuan was provided
.
In general, under the pressure of a series of policies, the elimination process of the pharmaceutical market will continue to accelerate
.
Especially in the next 3 to 5 years, the knockout stage of the pharmaceutical industry will continue to accelerate, or 90% of generic drugs will withdraw from the market
.
It is worth noting that, at the same time, with the policy of consistency evaluation becoming clearer and the rules of drug bidding becoming more and more perfect, returning to value will be the future development direction of the industry
.
In this context, in order to obtain more development opportunities, enterprises must either expand the scale, improve quality, control costs, and improve supply management; or increase investment in research and development of new drugs; or enter the market and expand the field of drug research and development and sales
.
Among the many ways out, analysts believe that because national policies have been focusing on medicine in recent years, innovation will play a decisive role in the development of China's pharmaceutical industry, which will further promote the development of China's innovative drug market
.
In order to seize new market development opportunities, companies need to continuously increase investment in innovative drug research and development or promote the development of generic drugs with core values
.
It is reported that in fact, a large number of pharmaceutical companies have already transformed into innovative drugs and have gradually entered the harvest period
.
Taking Hengrui Medicine as an example, its innovative drug pipeline layout is already very rich.
In addition to blockbuster products such as PD-1, apatinib, pyrotinib, and fluzoparib, its innovative drug pipeline also covers A variety of indications have been developed, and the clinical progress of many potential products is also very smooth
.
